|Bid||3.00 x 800|
|Ask||16.03 x 800|
|Day's Range||5.64 - 6.13|
|52 Week Range||2.13 - 6.50|
|Beta (3Y Monthly)||-0.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these symptoms stabilized or improved with treatment.
XBiotech (XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints.
XBiotech Inc. (XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product. XBiotech manufactures bermekimab at its campus facility in Austin, Texas and regularly ships the drug to clinics in various countries in the European Union and the United Kingdom.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
XBiotech Inc. (XBIT) today provided an update on recent company developments in its third quarter Form 10-Q filing with the SEC. The Company reports that it continues to make important progress in its clinical and pre-clinical programs in addition to other corporate initiatives. In April 2018, XBiotech announced the launch of a Phase 2, open label clinical trial to evaluate the Company’s True Human™ monoclonal antibody, bermekimab, in patients with moderate to severe Atopic Dermatitis (AD).
XBiotech Inc. (XBIT) announced today that it was awarded 11 new patents or patent allowances in the third quarter of 2018. Patents issued relate to the Company’s drug candidates bermekimab and 514G3, which target a crucial mediator of chronic inflammation and Staphylococcus aureus (including MRSA), respectively.
AUSTIN, Texas, Oct. 24, 2018 -- XBiotech Inc. (NASDAQ: XBIT) announced today that the honorable Judge Dustin M. Howell of the 459th Travis County District Court has issued a.
AUSTIN, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating ...
XBiotech Inc. (XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating MABp1 in patients with moderate to severe Atopic Dermatitis (AD). The patient began treatment at Florida Academic Dermatology Center under the care of the Study`s Chair, Dr. Francisco Kerdel.
XBiotech to Launch Two Phase 2 Clinical Studies to Study Subcutaneous Administration of MABp1 for Treatment of Hidradenitis Suppurativa and Atopic Dermatitis AUSTIN, Texas, April 16, 2018 (GLOBE NEWSWIRE) ...
Agreement Centers on XBiotech`s Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7 AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) announced ...
LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on XBiotech Inc. (NASDAQ: XBIT ). If you want access to this report all you need to do is sign ...
Data Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) Provide Results that Corroborate HiSCR findings with iHS4 Scoring as a Measure of Efficacy AUSTIN, Texas, ...